Correction: Transforming histologic assessment: artificial intelligence in cancer diagnosis and personalized treatment.

Predictive modeling in reproductive medicine: Where will the future of artificial intelligence research take us?

Leaving cancer diagnosis to the computers

Cancer screening and diagnosis with the utilization of innovative Artificial Intelligence tools improved the treatment strategies and patients’ survival. With the rapid development of imaging technologies and the rise of artificial intelligence (AI), there is a significant opportunity to improve cancer diagnostics through the combination of image analysis and AI algorithms. This article provides a comprehensive review of studies that have investigated the application of AI-assisted image processing in cancer diagnosis. We searched the Web of Science and Scopus databases to identify relevant studies published between 2014 and January 2024. The search strategy utilized targeted keywords such as cancer diagnostics, image analysis, artificial intelligence, and advanced imaging techniques. We limited the review to articles written in English and using AI-assisted image processing in cancer diagnosis. The results show that by leveraging machine learning algorithms, including deep learning, computer-aided diagnosis systems have been developed that are efficient in detecting tumors, thereby facilitating early cancer detection. Additionally, various authors have explored the integration of personalized treatment approaches and precision medicine, allowing for the development of treatment plans tailored to individual patient characteristics and needs. The review emphasizes the potential of AI-assisted image processing in revolutionizing cancer diagnostics. The insights gained from this study contribute to the current understanding of the field and pave the way for future research and development aimed at advancing cancer diagnostics using image analysis and artificial intelligence.

Can Artificial Intelligence (AI) assist in the diagnosis of oral mucosal lesions and/or oral cancer?

Simple SummaryArtificial Intelligence (AI) has been increasingly used in radiology to improve diagnostic procedures over the past decades. The application of AI at the time of cancer diagnosis also creates challenges in the way doctors should communicate the use of AI to patients. The present systematic review deals with the patient’s psycho-cognitive perspective on AI and the interpersonal skills between patients and physicians when AI is implemented in cancer diagnosis communication. Evidence from the retrieved studies pointed out that the use of AI in radiology is negatively associated with patient trust in AI and patient-centered communication in cancer disease.Background: In the past decade, interest in applying Artificial Intelligence (AI) in radiology to improve diagnostic procedures increased. AI has potential benefits spanning all steps of the imaging chain, from the prescription of diagnostic tests to the communication of test reports. The use of AI in the field of radiology also poses challenges in doctor–patient communication at the time of the diagnosis. This systematic review focuses on the patient role and the interpersonal skills between patients and physicians when AI is implemented in cancer diagnosis communication. Methods: A systematic search was conducted on PubMed, Embase, Medline, Scopus, and PsycNet from 1990 to 2021. The search terms were: (“artificial intelligence” or “intelligence machine”) and “communication” “radiology” and “oncology diagnosis”. The PRISMA guidelines were followed. Results: 517 records were identified, and 5 papers met the inclusion criteria and were analyzed. Most of the articles emphasized the success of the technological support of AI in radiology at the expense of patient trust in AI and patient-centered communication in cancer disease. Practical implications and future guidelines were discussed according to the results. Conclusions: AI has proven to be beneficial in helping clinicians with diagnosis. Future research may improve patients’ trust through adequate information about the advantageous use of AI and an increase in medical compliance with adequate training on doctor–patient diagnosis communication.

BackgroundArtificial intelligence (AI) has emerged as a transformative tool in oncology, offering promising applications in chemotherapy development, cancer diagnosis, and predicting chemotherapy response. Despite its potential, debates persist regarding the predictive accuracy of AI technologies, particularly machine learning (ML) and deep learning (DL).ObjectiveThis review aims to explore the role of AI in forecasting outcomes related to chemotherapy development, cancer diagnosis, and treatment response, synthesizing current advancements and identifying critical gaps in the field.MethodsA comprehensive literature search was conducted across PubMed, Embase, Web of Science, and Cochrane databases up to 2023. Keywords included “Artificial Intelligence (AI),” “Machine Learning (ML),” and “Deep Learning (DL)” combined with “chemotherapy development,” “cancer diagnosis,” and “cancer treatment.” Articles published within the last four years and written in English were included. The Prediction Model Risk of Bias Assessment tool was utilized to assess the risk of bias in the selected studies.ConclusionThis review underscores the substantial impact of AI, including ML and DL, on cancer diagnosis, chemotherapy innovation, and treatment response for both solid and hematological tumors. Evidence from recent studies highlights AI’s potential to reduce cancer-related mortality by optimizing diagnostic accuracy, personalizing treatment plans, and improving therapeutic outcomes. Future research should focus on addressing challenges in clinical implementation, ethical considerations, and scalability to enhance AI’s integration into oncology care.

e13553 Background: Mammography interpretation presents some challenges however, better technological approaches have allowed increased accuracy in cancer diagnosis and nowadays, radiologists sensitivity and specificity for mammography screening vary from 84.5 to 90.6 and 89.7 to 92.0%, respectively. Since its introduction in breast image analysis, artificial intelligence (AI) has rapidly improved and deep learning methods are gaining relevance as a companion tool to radiologists. Thus, the aim of this systematic review and meta analysis was to evaluate the sensitivity and specificity of AI deep learning algorithms and radiologists for breast cancer detection through mammography. Methods: A systematic review was performed using PubMed and the words: deep learning or convolutional neural network and mammography or mammogram, from January 2015 to October 2020. All titles and abstracts were doubly checked; duplicate studies and studies in languages other than English were excluded. The remaining complete studies were doubly assessed and those with specificity and sensibility information had data collected. For the meta analysis, studies reporting specificity, sensitivity and confidence intervals were selected. Heterogeneity measures were calculated using Cochran Q test (chi-square test) and the I2 (percentage of variation). Sensitivity and specificity and 95% confidence intervals (CI) values were calculated, using Stata/MP 14.0 for Windows. Results: Among 223 studies, 66 were selected for full paper analysis and 24 were selected for data extraction. Subsequently, only papers evaluating sensitivity, especificity, CI and/or AUC were analyzed. Eleven studies compared AUC using AI with another method and for these studies, a differential AUC was calculated, however no differences were observed: AI vs Reader (n = 3; p = 0.109); AI vs AI (n = 5; p = 0.225); AI vs AI + reader (n = 2; p = 0.180); AI + Reader vs reader (n = 2; p = 0.655); AI vs reader (n > 1) (n = 3; p = 0.102). Some studies had more than one comparison. A meta analysis was performed to evaluate sensitivity and specificity of the methods. Five studies were included in this analysis and a great heterogeneity among them was observed. There were studies evaluating more than one AI algorithm and studies comparing AI with readers alone or in combination with AI. Sensitivity for AI; AI + reader; reader alone, were 76.08; 84.02; 80.91, respectively. Specificity for AI; AI + reader; reader alone, were 96.62; 85.67; 84.89, respectively. Results are shown in the table. Conclusions: Although recent improvements in AI algorithms for breast cancer screening, a delta AUC between comparisons of AI algorithms and readers was not observed.[Table: see text]

Can artificial intelligence improve cancer care?

Artificial intelligence (AI) is the newly developed intelligent technology that can simulate human brain to establish neural network and even extent human capacity. Recently, deep dig of medical big data is owing to breakthrough of AI technology and deep learning algorithm. New model of AI plus medical creation is promoted. This review will discuss AI applications and theories in medical fields, especially in cancer diagnosis and treatment. This contains the advantages of AI in image disposes (imaging and pathology), radiomics which pave the road for AI technology, newly developed deep learning algorithm. We will also discuss the main usages of AI in the diagnosis, characteristics and monitoring of cancers. As the accumulating experiences of AI application in diseases, deep learning can explore more and more medical data to train and validate established models. We anticipate the performance will be greatly improved in the future, and even surpass accuracy and sensitivity of imaging experts and pathologists in cancer diagnosis and treatment. Key words: Artificial Intelligence; Malignancy; Deep learning; Diagnosis

The last decade has witnessed major advances in the development of artificial intelligence (AI) technologies for use in health care. One of the most promising areas of research that has potential clinical utility is the use of AI in pathology to aid cancer diagnosis and management. While the value of using AI to improve the efficiency and accuracy of diagnosis cannot be underestimated, there are challenges in the development and implementation of such technologies. Notably, questions remain about public support for the use of AI to assist in pathological diagnosis and for the use of health care data, including data obtained from tissue samples, to train algorithms. This study aimed to investigate public awareness of and attitudes toward AI in pathology research and practice. A nationally representative, cross-sectional, web-based mixed methods survey (N=1518) was conducted to assess the UK public's awareness of and views on the use of AI in pathology research and practice. Respondents were recruited via Prolific, an online research platform. To be eligible for the study, participants had to be aged >18 years, be UK residents, and have the capacity to express their own opinion. Respondents answered 30 closed-ended questions and 2 open-ended questions. Sociodemographic information and previous experience with cancer were collected. Descriptive and inferential statistics were used to analyze quantitative data; qualitative data were analyzed thematically. Awareness was low, with only 23.19% (352/1518) of the respondents somewhat or moderately aware of AI being developed for use in pathology. Most did not support a diagnosis of cancer (908/1518, 59.82%) or a diagnosis based on biomarkers (694/1518, 45.72%) being made using AI only. However, most (1478/1518, 97.36%) supported diagnoses made by pathologists with AI assistance. The adjusted odds ratio (aOR) for supporting AI in cancer diagnosis and management was higher for men (aOR 1.34, 95% CI 1.02-1.75). Greater awareness (aOR 1.25, 95% CI 1.10-1.42), greater trust in data security and privacy protocols (aOR 1.04, 95% CI 1.01-1.07), and more positive beliefs (aOR 1.27, 95% CI 1.20-1.36) also increased support, whereas identifying more risks reduced the likelihood of support (aOR 0.80, 95% CI 0.73-0.89).In total, 3 main themes emerged from the qualitative data: bringing the public along, the human in the loop, and more hard evidence needed, indicating conditional support for AI in pathology with human decision-making oversight, robust measures for data handling and protection, and evidence for AI benefit and effectiveness. Awareness of AI's potential use in pathology was low, but attitudes were positive, with high but conditional support. Challenges remain, particularly among women, regarding AI use in cancer diagnosis and management. Apprehension persists about the access to and use of health care data by private organizations.

We study the performance of an artificial intelligence (AI) program designed to assist radiologists in the diagnosis of breast cancer, relative to measures obtained from conventional readings by radiologists. A total of 10 radiologists read a curated, anonymized group of 299 breast ultrasound images that contained at least one suspicious lesion and for which a final diagnosis was independently determined. Separately, the AI program was initialized by a lead radiologist and the computed results compared against those of the radiologists. The AI program's diagnoses of breast lesions had concordance with the 10 radiologists' readings across a number of BI-RADS descriptors. The sensitivity, specificity, and accuracy of the AI program's diagnosis of benign versus malignant was above 0.8, in agreement with the highest performing radiologists and commensurate with recent studies. The trained AI program can contribute to accuracy of breast cancer diagnoses with ultrasound.

BackgroundArtificial Intelligence (AI) is significantly transforming dermatology, particularly in early skin cancer detection and diagnosis. This technological advancement addresses a crucial public health issue by enhancing diagnostic accuracy, efficiency, and accessibility. AI integration in medical imaging and diagnostic procedures offers promising solutions to the limitations of traditional methods, which often rely on subjective clinical evaluations and histopathological analyses. This study systematically reviews current AI applications in skin cancer classification, providing a comprehensive overview of their advantages, challenges, methodologies, and functionalities.MethodologyIn this study, we conducted a comprehensive analysis of artificial intelligence (AI) applications in the classification of skin cancer. We evaluated publications from three prominent journal databases: Scopus, IEEE, and MDPI. We conducted a thorough selection process using the PRISMA guidelines, collecting 1,156 scientific articles. Our methodology included evaluating the titles and abstracts and thoroughly examining the full text to determine their relevance and quality. Consequently, we included a total of 95 publications in the final study. We analyzed and categorized the articles based on four key dimensions: advantages, difficulties, methodologies, and functionalities.ResultsAI-based models exhibit remarkable performance in skin cancer detection by leveraging advanced deep learning algorithms, image processing techniques, and feature extraction methods. The advantages of AI integration include significantly improved diagnostic accuracy, faster turnaround times, and increased accessibility to dermatological expertise, particularly benefiting underserved areas. However, several challenges remain, such as concerns over data privacy, complexities in integrating AI systems into existing workflows, and the need for large, high-quality datasets. AI-based methods for skin cancer detection, including CNNs, SVMs, and ensemble learning techniques, aim to improve lesion classification accuracy and increase early detection. AI systems enhance healthcare by enabling remote consultations, continuous patient monitoring, and supporting clinical decision-making, leading to more efficient care and better patient outcomes.ConclusionsThis comprehensive review highlights the transformative potential of AI in dermatology, particularly in skin cancer detection and diagnosis. While AI technologies have significantly improved diagnostic accuracy, efficiency, and accessibility, several challenges remain. Future research should focus on ensuring data privacy, developing robust AI systems that can generalize across diverse populations, and creating large, high-quality datasets. Integrating AI tools into clinical workflows is critical to maximizing their utility and effectiveness. Continuous innovation and interdisciplinary collaboration will be essential for fully realizing the benefits of AI in skin cancer detection and diagnosis.

Over the past decade, artificial intelligence (AI) has contributed substantially to the resolution of various medical problems, including cancer. Deep learning (DL), a subfield of AI, is characterized by its ability to perform automated feature extraction and has great power in the assimilation and evaluation of large amounts of complicated data. On the basis of a large quantity of medical data and novel computational technologies, AI, especially DL, has been applied in various aspects of oncology research and has the potential to enhance cancer diagnosis and treatment. These applications range from early cancer detection, diagnosis, classification and grading, molecular characterization of tumors, prediction of patient outcomes and treatment responses, personalized treatment, automatic radiotherapy workflows, novel anti‐cancer drug discovery, and clinical trials. In this review, we introduced the general principle of AI, summarized major areas of its application for cancer diagnosis and treatment, and discussed its future directions and remaining challenges. As the adoption of AI in clinical use is increasing, we anticipate the arrival of AI‐powered cancer care.

Background A priori identification of patients at risk of artificial intelligence (AI) failure in diagnosing cancer would contribute to the safer clinical integration of diagnostic algorithms. Purpose To evaluate AI prediction variability as an uncertainty quantification (UQ) metric for identifying cases at risk of AI failure in diagnosing cancer at MRI and CT across different cancer types, data sets, and algorithms. Materials and Methods Multicenter data sets and publicly available AI algorithms from three previous studies that evaluated detection of pancreatic cancer on contrast-enhanced CT images, detection of prostate cancer on MRI scans, and prediction of pulmonary nodule malignancy on low-dose CT images were analyzed retrospectively. Each task's algorithm was extended to generate an uncertainty score based on ensemble prediction variability. AI accuracy percentage and partial area under the receiver operating characteristic curve (pAUC) were compared between certain and uncertain patient groups in a range of percentile thresholds (10%-90%) for the uncertainty score using permutation tests for statistical significance. The pulmonary nodule malignancy prediction algorithm was compared with 11 clinical readers for the certain group (CG) and uncertain group (UG). Results In total, 18 022 images were used for training and 838 images were used for testing. AI diagnostic accuracy was higher for the cases in the CG across all tasks (P < .001). At an 80% threshold of certain predictions, accuracy in the CG was 21%-29% higher than in the UG and 4%-6% higher than in the overall test data sets. The lesion-level pAUC in the CG was 0.25-0.39 higher than in the UG and 0.05-0.08 higher than in the overall test data sets (P < .001). For pulmonary nodule malignancy prediction, accuracy of AI was on par with clinicians for cases in the CG (AI results vs clinician results, 80% [95% CI: 76, 85] vs 78% [95% CI: 70, 87]; P = .07) but worse for cases in the UG (AI results vs clinician results, 50% [95% CI: 37, 64] vs 68% [95% CI: 60, 76]; P < .001). Conclusion An AI-prediction UQ metric consistently identified reduced performance of AI in cancer diagnosis. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Babyn in this issue.

Simple SummaryOral cancer is characterized by high morbidity and mortality, since the disease is typically in an advanced locoregional stage at the time of diagnosis. The application of artificial intelligence (AI) techniques to oral cancer screening has recently been proposed. This scoping review analyzed the information about different machine learning tools in support of non-invasive diagnostic techniques including telemedicine, medical images, fluorescence images, exfoliative cytology and predictor variables at risk of developing oral cancer. The results suggest that such tools can make a noninvasive contribution to the early diagnosis of oral cancer and we express the gaps of the proposed questions to be improved in new investigations.The early diagnosis of cancer can facilitate subsequent clinical patient management. Artificial intelligence (AI) has been found to be promising for improving the diagnostic process. The aim of the present study is to increase the evidence on the application of AI to the early diagnosis of oral cancer through a scoping review. A search was performed in the PubMed, Web of Science, Embase and Google Scholar databases during the period from January 2000 to December 2020, referring to the early non-invasive diagnosis of oral cancer based on AI applied to screening. Only accessible full-text articles were considered. Thirty-six studies were included on the early detection of oral cancer based on images (photographs (optical imaging and enhancement technology) and cytology) with the application of AI models. These studies were characterized by their heterogeneous nature. Each publication involved a different algorithm with potential training data bias and few comparative data for AI interpretation. Artificial intelligence may play an important role in precisely predicting the development of oral cancer, though several methodological issues need to be addressed in parallel to the advances in AI techniques, in order to allow large-scale transfer of the latter to population-based detection protocols.